Eugia US LLC has initiated a voluntary nationwide recall of one specific lot (3VM26026A) of Vancomycin Hydrochloride for Injection 1.25 g/vial. This action was taken after the discovery of particulate matter, specifically glass fragments, inside the vial.

The recall notification was announced by Eugia US LLC on November 6, 2026, with the U.S. Food and Drug Administration publishing the information on November 9, 2026. The company and the FDA emphasize patient safety as the primary motivation for this recall.

Healthcare professionals and facilities are advised to check their inventories for the affected lot number and to discontinue use immediately. Further instructions will typically be provided by the manufacturer or regulatory bodies.

Patients receiving Vancomycin Hydrochloride for Injection should consult their healthcare providers regarding any concerns or adverse effects potentially related to this recall. Monitoring and communication remain crucial to ensure safety and effective treatment.